Filing Flows › Seres Therapeutics (MCRB) › Q2 2026 › vs Q1 2026
Seres Therapeutics (MCRB) Q2 2026 vs Q1 2026 (quarter over quarter)
Seres Therapeutics's revenue rose $378K (+106%) from $358K in Q1 2026 to $736K in Q2 2026.
Seres Therapeutics, Q2 2026: revenue $736K, net earnings $4.6M, operating cash flow −$22.4M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $736K | $358K | $378K | +106% |
| Other income, net | $25.9M | $994K | $24.9M | 26× |
| Costs & expenses | $26.6M | $21.3M | $5.3M | +25% |
| Operating costs | $22.0M | $21.3M | $744K | +3% |
| Net earnings | $4.6M | −$19.9M | $24.5M | — |
| Research & development | $9.1M | $13.2M | −$4.1M | -31% |
| General & admin | $7.1M | $8.1M | −$1.0M | -13% |
| Operating cash sources | $29.4M | −$1.0M | $30.4M | — |
| Depreciation & amortization | $670K | $781K | −$111K | -14% |
| Share-based compensation | $1.7M | $1.8M | −$27K | -2% |
| Cash used in operations | $22.4M | $16.4M | $6.0M | +37% |
| Working capital & other | $29.4M | −$1.0M | $30.4M | — |
Questions
How much did Seres Therapeutics's revenue grow quarter over quarter in Q2 2026?
Seres Therapeutics's revenue rose $378K (+106%) from $358K in Q1 2026 to $736K in Q2 2026.